Xtalpi Inc. Makes a Splash with HKD 1.13 Billion IPO on Hong Kong Stock Exchange
XtalPi (QuantumPharm, HKG: 2228) has successfully conducted an initial public offering (IPO) on the Hong...
Chia Tai Tianqing Pharmaceutical
Chia Tai Tianqing’s PD-L1 Antibody Benmelstobart Wins NMPA Nod for ES-SCLC
China-based Chia Tai Tianqing has announced that it has received marketing approval from the National...
Chia Tai Tianqing’s TQA3038 siRNA Drug Completes Phase I Clinical Trial for Chronic Hepatitis B
Chia Tai Tianqing has announced the successful completion of a Phase I clinical study for...
Chia Tai Tianqing’s Rovadicitinib Meets Main Goal in Myelofibrosis Trial, Eyes Market Filing
Chia Tai Tianqing, a renowned pharmaceutical company based in China, has declared that it has...
Kexing Pharmaceutical Secures Rights for Chia Tai Tianqing’s Generic Ibrance in 11 Countries
Kexing Pharmaceutical (SHA: 688136), based in China, has entered into an international collaboration agreement with...
Chia Tai Tianqing’s Anlotinib-Benmelstobart Combo Therapy Receives CDE Review for Endometrial Cancer
Chia Tai Tianqing, a renowned biopharmaceutical company based in China, has announced that the Center...
Chia Tai Tianqing and Fudan University Shanghai Cancer Center Join Forces for Innovative Drug Development
Chia Tai Tianqing, a China-based pharmaceutical company, has entered into a strategic partnership with Fudan...
Akeso Biopharma Files New Indication for Penpulimab in First-Line NPC Treatment
Akeso Biopharma (HKG: 9926) has announced a new indication filing for its programmed death-1 (PD-1)...
Chia Tai Tianqing’s Generic Entresto Approved by NMPA, Launch Expected in 2026
The National Medical Products Administration (NMPA) website has indicated that Chia Tai Tianqing’s generic version...
Chia Tai Tianqing Secures Exclusive Rights to InventisBio’s D-1553 in China Licensing Deal
China-based Chia Tai Tianqing has signed a licensing agreement with compatriot firm InventisBio, securing exclusive...
Eli Lilly’s Mirikizumab and Chia Tai Tianqing’s Lanifibranor Enter Breakthrough Therapy Review
US pharmaceutical major Eli Lilly’s (NYSE: LLY) mirikizumab and China-based Chia Tai Tianqing’s lanifibranor have...
Beijing Intellectual Property Court Upholds Validity of Novartis’ Entresto Patent
The Beijing Intellectual Property Court (BIPC) has issued a judgment that reaffirms the validity and...
Chia Tai Tianqing Launches First Batch of F-627 for Neutropenia Treatment in China
China-based Chia Tai Tianqing has announced the first batch prescriptions in China for its efbemalenograstim...
Sino Biopharmaceutical Secures Exclusive Rights to Gmax Biopharm’s GMA106 in Greater China
Sino Biopharmaceutical Ltd (HKG: 1177) through its subsidiary Chia Tai Tianqing Pharmaceutical Co., Ltd, has...
Chia Tai Tianqing’s Biosimilar Rituximab Approved by China’s NMPA for Lymphoma Treatments
China-based Chia Tai Tianqing has announced receiving a market approval from the National Medical Products...
Chia Tai Tianqing’s TQ-B3525 Heads for Priority Review for Recurrent Follicular Lymphoma
The Center for Drug Evaluation (CDE) website has indicated that Chia Tai Tianqing’s TQ-B3525, a...
Yifan Pharmaceutical’s F-627 Receives NMPA Approval for Neutropenia Treatment in Cancer Patients
Yifan Pharmaceutical Co., Ltd (SHE: 002019), a China-based pharmaceutical company, has announced receiving market approval...
Specialised Therapeutics to Commercialize Akeso’s PD-1 Inhibitor Penpulimab in APAC
Singapore-based Specialised Therapeutics Asia Pte Ltd (ST) has been appointed to handle the commercialization of...
Shenzhen Hepalink’s Subsidiary Techdow USA Secures Distribution Rights for ANDA-Approved Drug
China-based Shenzhen Hepalink Pharmaceutical Group Co., Ltd (SHE: 002399) has announced that its wholly owned...
CDE Grants Priority Review Status to TQB3454, HLX208, and Infigratinib for Cancer Treatments
The Center for Drug Evaluation (CDE) website has indicated that Chia Tai Tianqing’s TQB3454, Henlius...